RAPGEF3 and heart failure: EPAC1 activation offers significant promise in addressing critical conditions such as heart failure, type 2 diabetes, idiopathic pulmonary fibrosis (IPF), and vascular complications through its ability to modulate intracellular calcium handling, enhance endothelial barrier function, and regulate fibroblast activity.